share_log

Investors in China Nuclear Engineering (SHSE:601611) Have Unfortunately Lost 16% Over the Last Five Years

Investors in China Nuclear Engineering (SHSE:601611) Have Unfortunately Lost 16% Over the Last Five Years

不幸的是,中國核工程(SHSE: 601611)的投資者在過去五年中損失了16%
Simply Wall St ·  03/22 19:59

For many, the main point of investing is to generate higher returns than the overall market. But every investor is virtually certain to have both over-performing and under-performing stocks. At this point some shareholders may be questioning their investment in China Nuclear Engineering Corporation Limited (SHSE:601611), since the last five years saw the share price fall 19%.

對於許多人來說,投資的要點是產生比整個市場更高的回報。但是,幾乎每個投資者都肯定會有表現過硬和表現不佳的股票。目前,一些股東可能會質疑他們對中國核工程股份有限公司(SHSE: 601611)的投資,因爲在過去五年中,股價下跌了19%。

Now let's have a look at the company's fundamentals, and see if the long term shareholder return has matched the performance of the underlying business.

現在讓我們來看看公司的基本面,看看長期股東回報是否與基礎業務的表現相匹配。

To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.

用本傑明·格雷厄姆的話來說:從短期來看,市場是一臺投票機器,但從長遠來看,它是一臺稱重機。評估公司情緒變化的一種有缺陷但合理的方法是將每股收益(EPS)與股價進行比較。

While the share price declined over five years, China Nuclear Engineering actually managed to increase EPS by an average of 12% per year. So it doesn't seem like EPS is a great guide to understanding how the market is valuing the stock. Alternatively, growth expectations may have been unreasonable in the past.

儘管股價在五年內下跌,但中國核工程實際上設法做到了 增加 每股收益平均每年增長12%。因此,每股收益似乎不是了解市場如何估值股票的好指南。或者,過去的增長預期可能不合理。

Generally speaking we'd expect to see stronger share price increases on the back of sustained EPS growth, but other metrics may hold a clue to why the share price performance is relatively modest.

總的來說,在每股收益持續增長的背景下,我們預計股價將出現更強勁的上漲,但其他指標可能爲股價表現相對溫和提供了線索。

The modest 1.1% dividend yield is unlikely to be guiding the market view of the stock. In contrast to the share price, revenue has actually increased by 14% a year in the five year period. So it seems one might have to take closer look at the fundamentals to understand why the share price languishes. After all, there may be an opportunity.

1.1%的適度股息收益率不太可能指導該股的市場觀點。與股價形成鮮明對比的是,在五年期間,收入實際上每年增長14%。因此,看來人們可能必須仔細研究基本面才能理解股價下跌的原因。畢竟,可能有機會。

The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).

下圖描述了收入和收入隨時間推移而發生的變化(點擊圖片即可顯示確切的數值)。

earnings-and-revenue-growth
SHSE:601611 Earnings and Revenue Growth March 22nd 2024
SHSE: 601611 2024 年 3 月 22 日收益和收入增長

Balance sheet strength is crucial. It might be well worthwhile taking a look at our free report on how its financial position has changed over time.

資產負債表的強度至關重要。可能值得一看我們關於其財務狀況如何隨着時間的推移而變化的免費報告。

What About Dividends?

分紅呢?

It is important to consider the total shareholder return, as well as the share price return, for any given stock. The TSR incorporates the value of any spin-offs or discounted capital raisings, along with any dividends, based on the assumption that the dividends are reinvested. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. We note that for China Nuclear Engineering the TSR over the last 5 years was -16%, which is better than the share price return mentioned above. This is largely a result of its dividend payments!

重要的是要考慮任何給定股票的股東總回報率和股價回報率。基於股息再投資的假設,股東總回報率納入了任何分拆或貼現資本籌集的價值以及任何股息。可以公平地說,股東總回報率爲支付股息的股票提供了更完整的畫面。我們注意到,對於中國核工而言,過去5年的股東總回報率爲-16%,好於上述股價回報率。這在很大程度上是其股息支付的結果!

A Different Perspective

不同的視角

China Nuclear Engineering shareholders are down 12% over twelve months (even including dividends), which isn't far from the market return of -12%. Unfortunately, last year's performance is a deterioration of an already poor long term track record, given the loss of 3% per year over the last five years. Weak performance over the long term usually destroys market confidence in a stock, but bargain hunters may want to take a closer look for signs of a turnaround. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Case in point: We've spotted 2 warning signs for China Nuclear Engineering you should be aware of, and 1 of them is a bit concerning.

中國核工程股東在十二個月內下跌了12%(甚至包括股息),與-12%的市場回報率相差不遠。不幸的是,鑑於過去五年中每年虧損3%,去年的表現比本已糟糕的長期記錄有所惡化。長期表現疲軟通常會破壞市場對股票的信心,但討價還價者可能需要仔細觀察轉機的跡象。我發現將長期股價視爲業務績效的代表非常有趣。但是,要真正獲得見解,我們還需要考慮其他信息。一個很好的例子:我們發現了你應該注意的2箇中國核工程警告信號,其中一個有點令人擔憂。

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.

當然,通過尋找其他地方,你可能會找到一筆不錯的投資。因此,請看一下我們預計收益將增加的這份免費公司名單。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

請注意,本文引用的市場回報反映了目前在中國交易所交易的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論